Communiqués ASKA Pharmaceutical Holdings Co.,Ltd.

Actions

4886

JP3119660003

Produits pharmaceutiques

Marché Fermé - Japan Exchange Autres places de cotation 08:30:00 17/07/2026			Varia. 5j.	Varia. 1 janv.
2 244,00 ^JPY	+1,40%		-0,66%	+10,11%

27/05	Dalton Investment s'oppose fermement à l'activation conditionnelle des mesures de défense annoncées par ASKA Pharmaceutical Holdings le 25 mai	RE
25/05	Aska Pharmaceutical : projet de soumettre aux actionnaires des mesures de défense contre une éventuelle acquisition massive de titres par Dalton et ses affiliés	RE

Communiqués

31/05/24	ASKA Pharmaceutical : May 31 2024 Licensing Agreement for Relugolix Combination Tablet for Endometriosis in the Gynecologic Disease Area	PU
25/04/24	ASKA Pharmaceutical : April 25 2024 Personnel Changes of ASKA Pharmaceutical Holdings' Subsidiaries	PU
26/03/24	ASKA Pharmaceutical : March 26 2024 ASKA Pharmaceutical Receives Approval for Partial Change of Manufacturing and Marketing Approval for RIFXIMA® TABLETS for Pediatric Indication	PU
21/03/24	ASKA Pharmaceutical : March 21 2024 Newsweek International Features ASKA Pharmaceutical	PU
14/11/23	ASKA Pharmaceutical : November 13 2023 ASKA Pharmaceutical Featured in a Special Feature in TIME Magazine	PU
22/09/23	ASKA Pharmaceutical : September 21 2023 ASKA Pharmaceutical Holdings Participates at 2nd Femtech Tokyo	PU
14/09/23	ASKA Pharmaceutical : September 14 2023 Newsweek International Features ASKA Pharmaceutical	PU
20/07/23	ASKA Pharmaceutical : July 20 2023 ASKA Pharmaceutical Initiates Domestic Phase I II Clinical Trial of Relugolix Combination Tablet (AKP-022)	PU
27/06/23	ASKA Pharmaceutical : June 27 2023 Personnel Changes of Corporate Officers and Board Members of ASKA Pharmaceutical Holdings Subsidiaries	PU
22/06/23	ASKA Pharmaceutical : June 22 2023 ASKA Pharmaceutical Files an Application for Partial Change of Manufacturing and Marketing Approval for RIFXIMA	PU
11/06/23	ASKA Pharmaceutical : June 12 2023 Matters Subject to Measures for Electronic Provision of the Notice of the 2nd Annual General Meeting of Shareholders	PU
11/06/23	ASKA Pharmaceutical : June 12 2023 NOTICE OF CONVOCATION OF THE 2nd ANNUAL GENERAL MEETING OF SHAREHOLDERS	PU
09/06/23	ASKA Pharmaceutical : June 9 2023 ASKA Pharmaceutical Terminates Joint Research Agreement regarding the Drug Discovery Targeting Specific Ion Channels with RaQualia Pharma	PU
24/04/23	ASKA Pharmaceutical : April 24 2023 ASKA Pharmaceutical Enters into a Comprehensive Business Alliance Agreement on Femtech	PU
21/04/23	ASKA Pharmaceutical : April 21 2023 ASKA Pharmaceutical Holdings Installs CO₂-Free Electricity and Solar Power Generation Facilities	PU
07/04/23	ASKA Pharmaceutical : April 7 2023 ASKA licensee Hyundai files New Drug Application in Korea for OC Drospirenone	PU
07/04/23	ASKA Pharmaceutical : April 7 2023 ASKA Pharmaceutical Terminates Option Agreement with KinoPharma regarding Cervical Dysplasia Treatment	PU
27/03/23	ASKA Pharmaceutical : March 27 2023 Personnel Change of ASKA Pharmaceutical	PU
06/03/23	ASKA Pharmaceutical : March 6 2023 Organizational and Personnel Changes of ASKA Pharmaceutical	PU
07/02/23	ASKA Pharmaceutical : February 7 2023 EME and ASKA Announce Collaboration Agreement on Creating Novel PharmaLogical® VHH to address an unmet medical need in Obstetrics and Gynecology	PU
26/08/22	ASKA Pharmaceutical : August 26 2022 Organizational and Personnel Changes of ASKA Pharmaceutical	PU
19/07/22	ASKA Pharmaceutical : July 19 2022 ASKA Pharmaceutical Signs a Co-promotion Agreement with Melody International for “Fetal Monitor iCTG” in Japan	PU
30/06/22	ASKA Pharmaceutical : June 30 2022 ASKA Pharmaceutical donates its medicine to Ukraine	PU
28/06/22	ASKA Pharmaceutical : June 28 2022 Personnel Changes of ASKA Pharmaceutical Holdings Subsidiaries	PU
23/06/22	ASKA Pharmaceutical : June 23 2022 Agreement for Drospirenone	PU